scholarly journals Comparison of ferric carboxymaltose versus Iron Sucrose for treatment of iron deficiency anemia in pregnancy.

2021 ◽  
Vol 28 (04) ◽  
pp. 481-484
Author(s):  
Hira Jamal ◽  
Humaira Zafar ◽  
Mubashra Naz ◽  
Umber Fatima ◽  
Anees Fatima
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Ferric Carboxymaltose ◽  
P Value ◽  
Iron Treatment ◽  
Group A ◽  
Group B

Objective: To compare the mean increase in hemoglobin level with ferric carboxymaltose injection and iron sucrose injection for the management of the pregnant females presenting with iron deficiency anemia. Study Design: Randomized Controlled Trial. Settings: Department of Obstetrics and Gynecology Madina Teaching Hospital affiliated with University medical and Dental College Faisalabad. Period: July 2019 to December 2019. Material & Method: A total number of 100 patients presented in OPD satisfying the selection criteria were enrolled in the study after permission from ethical committee. On enrollment, a detailed clinical history which include previous iron treatment including and chronic medical disorders was taken. Clinical examination was done. Investigations for anemia include hemoglobin, reticulocyte count, peripheral film and red cell indices, serum ferritin level and Hb electrophoresis if indicated. The patients were randomly divided in two groups. In group A, females were given ferric carboxymaltose and in group B, females were given iron sucrose. After calculating the total iron deficit, patients in group A were given intravenous FCM. Patients in group B were given IS. Follow up of the patient was done after 3 weeks of intravenous iron treatment. The baseline Hb and values after 3 weeks of intravenous iron treatment were compared between the FCM and IS groups and increase in Hb level calculated as mean and SD. Both groups were analyzed for rise in Hb level by using independent sample t test. P value < 0.05 was taken as significant. Results: A total 100 pregnant female were found eligible for study, and were randomized into two groups of 50 each. Mean increase in hemoglobin level with ferric carboxymaltose and iron sucrose was evaluated, it shows that baseline Hb was 8.84±0.68 in Group A and 8.78 ±0.76 in Group B, P value was 0.67, after treatment Hb was 12.02±0.89 in Group A and 10.92 ±0.99 in Group B. Mean increase was 3.18 ±0.60 in Group A and 2.14±0.81 in Group B. P value was 0.001. Conclusion: Ferric carboxymaltose significantly increase Hb level and restores the iron stores as compare to iron sucreose. FCM is safe and effective intravenous treatment for iron deficiency anemia in pregnancy. FCM has the advantages of single large dose administration and fewer hospital visit. FCM is most suitable drug for the treatment of patients with IDA who required quick replenishment of iron stores.

scholarly journals A Comparative Study to Evaluate the Efficacy and Safety of Single Dose Intravenous Iron Carboxymaltose vs Multidose Iron Sucrose in Postpartum Cases of Severe Iron Deficiency Anemia

2015 ◽  
Vol 7 (1) ◽  
pp. 18-21
Author(s):  
Ruchika Garg ◽  
Renu Rajvanshi
Keyword(s):  
Adverse Reaction ◽  
Single Dose ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Efficacy And Safety ◽  
Group A ◽  
Group B

ABSTRACT Objective To evaluate the efficacy and safety of single dose intravenous iron carboxymaltose vs multidose iron sucrose in postpartum cases of severe iron deficiency anemia. Materials and methods One hundred cases with iron deficiency anemia in postpartum patient were selected from postpartum wards and assigned in two groups of 50 each. In group A, iron carboxymaltose injection administered by intravenous infusion upto a maximum single dose of 20 ml of iron carboxymaltose injection (1000 mg of iron). In group B Iron sucrose was given as 200 mg elemental iron (2 ampules of 5 ml) in 100 ml of 0.9% normal saline infusion over 15 minute alternate days up to 5 days. All the patients were monitored for rise in hemoglobin level at 2, 4, 8 and 12 weeks of iron therapy, adverse effect and rise in hematological parameter at 4 weeks. Results In group A, mean Hb level rise is 3.95 g/dl and in group B, it is 3.32 g/dl at 4 weeks of initial therapy. In group A, 100% cases achieved target Hb at 12 weeks after therapy while in group B 98% cases achieved target Hb at 12 weeks after therapy. In group A, 12% cases have grade 1 adverse reaction while in group B, 20% cases have adverse reaction. Conclusion Administration of intravenous iron has a good clinical result, with minimum adverse reactions. Thus, we can conclude that intravenous iron carboxymaltose therapy is safe, convenient, more effective and faster acting than intravenous iron sucrose for treatment of severe iron deficiency anemia in postpartum patient. How to cite this article Garg R, Singh S, Singh S, Rajvanshi R. A Comparative Study to Evaluate the Efficacy and Safety of Single Dose Intravenous Iron Carboxymaltose vs Multidose Iron Sucrose in Postpartum Cases of Severe Iron Deficiency Anemia. J South Asian Feder Obst Gynae 2015;7(1):18-21.

scholarly journals A study for efficacy and safety of ferric carboxymaltose versus iron sucrose in iron deficiency anemia among pregnant women in tertiary care hospital

2019 ◽  
Vol 8 (6) ◽  
pp. 2280
Author(s):  
Divyani Agrawal ◽  
Deepa Lokwani Masand
Keyword(s):  
Iron Deficiency ◽  
Adverse Events ◽  
Pregnant Women ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Ferric Carboxymaltose ◽  
Efficacy And Safety ◽  
Anemia During Pregnancy

Background: Anemia is one of the common manageable problem among the pregnant women worldwide, which contributes to maternal and perinatal mortality. This study aims to compare the efficacy and safety of intravenous ferric carboxymaltose with intravenous iron sucrose in treating anemia during pregnancy. Objective of this study was to compare safety and efficacy of intravenous ferric carboxymaltose with intravenous ferric sucrose in iron deficiency anemia during pregnancy.Methods: It’s an interventional prospective study conducted in Department of Obstetrics and Gynecology at NIMS, Jaipur, Rajasthan, India constituting of 100 pregnant women. Group 1- 50 pregnant women were treated with intravenous ferric carboxymaltose and Group 2: 50 pregnant women were treated with intravenous iron sucrose. Hemoglobin and serum ferritin levels were measured pre and post treatment with parenteral iron therapy. The efficacy of intravenous ferric carboxymaltose in comparison to intravenous iron sucrose was assessed. The evaluation of safety and tolerance with the parenteral therapy was also performed.Results: Anemia during pregnancy was more prevalent among the reproductive age group and in multiparous women. The mean rise in the hemoglobin level with ferric carboxymaltose was 2.92 gm/dl and with that of iron, sucrose was 1.08 gm/dl. The man rise in the serum ferritin levels with ferric carboxymaltose was 64.97ng/ml and with iron sucrose was 31.64 ng/ml. Ferric carboxymaltose was observed to be safer with no adverse events in comparison to the Iron sucrose which was related with adverse events among 03 pregnant women.Conclusions: Intravenous ferric carboxymaltose was more efficacious and safer in comparison to intravenous iron sucrose among pregnant women. Hence, ferric carboxymaltose is the drug of choice in treatment of iron deficiency anemia during pregnancy.

scholarly journals To evaluate the efficacy and safety of intravenous bolus versus intravenous infusion of iron sucrose in pregnant women with severe iron deficiency anemia

2017 ◽  
Vol 6 (6) ◽  
pp. 2417
Author(s):  
Urvashi Verma ◽  
Saroj Singh ◽  
Shikha Singh ◽  
Anu Pathak ◽  
Poonam Yadav ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Gestational Age ◽  
Intravenous Infusion ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Intravenous Bolus ◽  
Medical College ◽  
Group A ◽  
Group B

Background: Objective of present study was to evaluate the efficacy and safety of intravenous bolus iron sucrose for iron deficiency anemia during pregnancy during second and third trimester women presenting at S.N. medical college, Agra.Methods: It was a prospective controlled trial and study was carried out in Department of Obstetrics and Gynecology, S.N. medical college, Agra in the year 2014-2016. 100Pregnant women with proved iron deficiency anemia having hemoglobin between 4-9gm/dl was included in this study. Total Iron deficit was calculated by standard formula. Target haemoglobin was 11gm/dl. Iron sucrose was administered by intravenous bolus and intravenous infusion techniques. Hemoglobin was repeated at 2 weeks, 4 weeks and 8 weeks after the last dose of intravenous iron sucroseResults: In Group A (bolus group n=50) 22 women had gestational age >24-28weeks and 20 women gestational age >18-24 weeks, with Mean gestational age of 24.36±3.78 weeks. In Group B (infusion group n=50) most of the patients 24 (48%) had gestational age >24-28 weeks, 18 (36%) had gestational age >18-24 weeks, with Mean gestational age of 24.94±3.51 weeks. Target hemoglobin was achieved in group A in all 50 (100%) cases and in group B in 49 (98%) cases. There were no allergic reactions.Conclusions: This study showed a significant improvement in the hemoglobin of the patients after receiving intravenous bolus and intravenous infusion of iron sucrose. Patients achieved the target hemoglobin of 11gm/dl. Both therapies are safe, effective and faster acting for the treatment of iron deficiency anaemia during pregnancy. The bolus push technique is more convenient to women and care provider, less time consuming as well as cost effective.

scholarly journals IRON DEFICIENCY ANEMIA

2007 ◽  
Vol 14 (02) ◽  
pp. 263-265
Author(s):  
RAHEELA FARHAT ◽  
DR. MAHNAAZ ROOHI
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Oral Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Safety And Efficacy ◽  
Deficiency Anaemia ◽  
Group A ◽  
Group B

Objective: To evaluate the safety and efficacy of intra venous iron sucrose(venofer) as comparedto oral iron in treatment of iron deficiency anaemia during pregnancy. Study Design: Prospective study. Pregnantwomen with iron deficiency anaemia were selected from ante natal clinic. Patients were divided into two groups. GroupA: These patients were given oral iron. Group B: These patients were given intravenous sucrose. All patients wereevaluated for adverse effects, clinical and laboratory response >. Results: Intravenous group achieved a higher Hblevel in a shorter period. Group B showed no major side effects while (80%) of patients in Group A developedgastrointestinal symptoms. Conclusion: Intravenous iron sucrose is safe and effective in treatment of iron deficiencyanemia during pregnancy.

scholarly journals Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia

Anemia ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Iftikhar Hussain ◽  
Jessica Bhoyroo ◽  
Angelia Butcher ◽  
Todd A. Koch ◽  
Andy He ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Deficiency Anemia ◽  
Ferric Carboxymaltose ◽  
Iron Dextran ◽  
Open Label ◽  
Safety Population ◽  
Group A ◽  
Labile Iron

Several intravenous iron complexes are available for the treatment of iron deficiency anemia (IDA). Iron dextran (DEX) is associated with an elevated risk of potentially serious anaphylactic reactions, whereas others must be administered in several small infusions to avoid labile iron reactions. Ferric carboxymaltose (FCM) is a nondextran intravenous iron which can be administered in high single doses. A randomized, open label, and multicenter comparison of FCM to DEX in adults with IDA and baseline hemoglobin of ≤11.0 g/dL was conducted. A total of 160 patients were in the safety population (FCMn=82; DEXn=78). Adverse events, including immune system disorders (0% in FCM versus 10.3% in DEX,P=0.003) and skin disorders (7.3% in FCM versus 24.4% in DEX,P=0.004), were less frequently observed in the FCM group. A greater portion of patients in the FCM group experienced a transient, asymptomatic decrease in phosphate compared to patients in the DEX group (8.5% in FCM versus 0% in DEX,P=0.014). In the FCM arm, the change in hemoglobin from baseline to the highest observed level was 2.8 g/dL, whereas the DEX arm displayed a change of 2.4 g/dL (P=0.20). Treatment of IDA with FCM resulted in fewer hypersensitivity-related reactions than DEX.

scholarly journals Intravenous iron sucrose in malnourished children with iron deficiency anemia.

2020 ◽  
Vol 27 (09) ◽  
pp. 1867-1871
Author(s):  
Fahad Nazir ◽  
Asim Khurshid ◽  
Muhammad Abu Talib
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Hemoglobin Level ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
P Value ◽  
Malnourished Children ◽  
Quasi Experimental ◽  
The Mean

Objectives: To compare the mean hemoglobin level before and six weeks after giving intravenous iron sucrose therapy in malnourished children having iron deficiency anemia. Study Design: Quasi Experimental Study. Setting: Nutritional Stabilization Centre, Children Hospital and Institute of Child Health, Multan. Period: From July 2018 to December 2018. Material & Methods: A total of 80 patients were enrolled in the study. Hemoglobin level at baseline was recorded. IV iron sucrose therapy was divided into 3 equal doses and administered on 3 consecutive days. After 6 weeks of administration of iron sucrose, hemoglobin level was noted. Independent sample T-test was applied to compare Hb level before and after therapy with p-value≤0.05 as significant. Results: Overall, mean age was 13.39±6.11months. There were 54 (67.5%) males and 28 (32.5%) females. The mean weight of patients was 5.06±1.45kg and mean height was 64.59±8.72cm. The weight for height ratio was <-3SD in all patients (100%). The mean hemoglobin level of patients at baseline was 7.37±0.44g/dl, which was improved to 9.47±0.47g/dl after 6 weeks treatment. This was significant improvement (p<0.05). Conclusion: Thus intravenous iron sucrose therapy can significantly improve the condition of child and rectify the IDA.

scholarly journals Comparative Study of Intravenous Iron Sucrose Vs Oral Ferrous Sulfate Therapy for Uncomplicated Iron Deficiency Anemia

2020 ◽  
Vol 27 (2) ◽  
pp. 175-181
Author(s):  
Dilshad Jahan ◽  
Mohammad Manirul Islam ◽  
Mohammad Zaid Hossain ◽  
Masuma Ahmed Salsabil ◽  
Iftadul Islam ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Oral Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Medical College ◽  
Group A ◽  
Iv Iron ◽  
Group B

Background: Iron deficiency anemia (IDA) is one of the most frequent nutritional deficiency leading to morbidity and mortality in whole world. Oral iron therapy as well as intravenous (IV) iron therapy can be given to treat the IDA patients. Objective: To compare the efficacy and hematological changes of Oral and IV iron preparation in patients with uncomplicated iron deficiency anemia. Method: An interventional, prospective study in patients with uncomplicated IDA anemia receiving IV iron sucrose and Oral iron ferrous sulfate were included. Clinical history, baseline hemoglobin, anemia indices data were recorded in a case record form. A total number of 80 patients were enrolled in this study. 40 patients (Group A) were treated with IV iron sucrose and another 40 patients (Group B) were treated with oral iron ferrous sulfate. After therapy Hemoglobin level, RBC indices and adverse drug reactions (ADRs) were observed. Place and period of Study: Study was carried out in the Department of Hematology at Dhaka Medical College Hospital (DMCH), from July 2015 to June 2016. Results: The mean age of total participants was 35.77 ± 16.08 (range of 13 – 75 years). In this study female (72.5%) is predominant than male (27.5%). Oral and IV iron preparations significantly (P<0.0001) improved mean hemoglobin, anemia indices at the end of study. However, mean increase in hemoglobin were significant (P<0.0001) with IV iron sucrose (7.6 ± 2.9) gm/dl, as compared to Oral ferrous sulfate (6.4± 2.2)gm/dl, after 2 months of therapy. In this study Hemoglobin increases in group A (IV iron arm) almost 1mg/kg/week and in group B (oral iron arm) 0.8 mg/dl/week).Surprisingly, ADRs were more in patients treated with oral ferrous sulfate (38%) compared to iron sucrose (26%). Conclusion: IV iron sucrose improves hemoglobin, anemia indices and replenish iron stores rapidly and is well tolerated than oral iron preparations. J Dhaka Medical College, Vol. 27, No.2, October, 2018, Page 175-181

Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy

1996 ◽  
Vol 69 (2) ◽  
pp. 121-124 ◽  
Author(s):  
Abdul-Kareem Al-Momen ◽  
Abdulaziz Al-Meshari ◽  
Lulu Al-Nuaim ◽  
Abdulaziz Saddique ◽  
Zainab Abotalib ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Anemia During Pregnancy
Sign in / Sign up

Export Citation Format

Share Document